MIT Creates Optical Sensor to Track Zinc in Cells - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MIT Creates Optical Sensor to Track Zinc in Cells


A new optical sensor created at the Massachusetts Institute of Technology (MIT) tracks zinc within cells and should help researchers learn more about its functions in cancerous cells, the university said in a press release. Measuring zinc levels may lead to a diagnostic test for early detection of prostrate cancer.  

The sensor, which can be targeted to a specific organelle within the cell, is added to cells in a laboratory dish and fluoresces when it binds to zinc, allowing scientists to determine where the metal is concentrated. The MIT chemists who designed the sensor have already used it to shed light on why zinc levels, normally high in the prostate, drop dramatically in cancerous prostate cells.

“We can use these tools to study zinc trafficking within prostate cells, both healthy and diseased. By doing so we’re trying to gain insight into how zinc levels within the cell change during the progression of prostate cancer,” says Robert Radford, an MIT postdoc who led the project and who is an author of the paper describing the sensors, which appears in the December 9th issue of the Proceedings of the National Academy of Sciences. Radford works in the lab of Stephen Lippard, the Arthur Amos Noyes Professor of Chemistry and senior author of the paper. The paper’s lead author is Wen Chyan, a 2013 MIT graduate. 

Researchers in Lippard’s laboratory are now working on exploiting similar fluorescent sensors to develop a diagnostic test for early detection of prostate cancer, which is the second leading cause of cancer death in American men, but is considered treatable if caught early enough.

A recent article published in Pharmaceutical Technology discusses other sensor technologies, including implantable and ingestible sensors that are being used to track and predict disease.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here